denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Description:
Until recently, treatment options for patients with newly diagnosed and relapsed/refractory acute myeloid leukemia (AML) were limited to cytotoxic chemotherapeutic agents that possessed little specificity for the cytogenetic and molecular mutations known to risk stratify patients with this disease. Furthermore, treatment was often started very soon after the diagnosis was made with limited consideration of these disease specific characteristics. The approval of the multi-targeted kinase inhibitor midostaurin for patients with FLT3 mutated AML in 2017 heralded the approval of eight additional agents and quickly ushered in a new age for the therapeutic management of this disease. Outside of emergent presentations, most patients with a new diagnosis of AML now undergo a complete molecular and cytogenetic evaluation that in many cases decides the treatment plan. As a result, not only have the agents that we treat patients with changed, the way that we talk about these options with patients, decide on, and manage therapy has been transformed.
Dr. Jacqueline S. Garcia will discuss one of the most debatable questions in the field, how does one determine whether a patient is “fit†for a therapy? Underlying fitness has been a central factor in determining initial treatment choice for patients diagnosed with AML. However, relatively effective non-intensive therapies are now available for patients with co-morbidities or those who are older than 75 years, which may change our approach. Genetic and functional determinants of response have become increasingly important in treatment decision making irrespective of chronological age. Dr. Garcia will provide insights and recommendations on how to approach fitness and treatment choice in patients newly diagnosed with AML.
Dr. Alison R. Walker will discuss recommendations for best practices to help guide the increasingly complex treatment discussions that are needed for patients at each stage of their disease. Once a complete remission has been achieved, the road to maximizing disease free and overall survival for AML patients may take different paths. How can we help patients make an informed decision, weighing the risk of relapse with patient wishes and desired quality of life? Dr. Walker will be discussing approaches to shared decision making in determining consolidation, maintenance, and transplantation for patients with AML.
Dr. Eunice S. Wang will discuss recommendations for the ongoing management of patients who are receiving these new treatments. While the advent of targeted therapies for AML has led to new hope for our patients, it has also introduced new challenges in management. Which patients benefit most from a specific therapy and what side effects should we watch for? When should you consider discontinuation of therapy? Are there patients who should move on to allogeneic stem cell transplantation rather than continue with the targeted agent? Dr. Wang will discuss the unique toxicities associated with mutation specific and non-specific agents and the risk/benefit ratio in decision making for individual patients.
Dr. Jacqueline S. Garcia will discuss one of the most debatable questions in the field, how does one determine whether a patient is “fit†for a therapy? Underlying fitness has been a central factor in determining initial treatment choice for patients diagnosed with AML. However, relatively effective non-intensive therapies are now available for patients with co-morbidities or those who are older than 75 years, which may change our approach. Genetic and functional determinants of response have become increasingly important in treatment decision making irrespective of chronological age. Dr. Garcia will provide insights and recommendations on how to approach fitness and treatment choice in patients newly diagnosed with AML.
Dr. Alison R. Walker will discuss recommendations for best practices to help guide the increasingly complex treatment discussions that are needed for patients at each stage of their disease. Once a complete remission has been achieved, the road to maximizing disease free and overall survival for AML patients may take different paths. How can we help patients make an informed decision, weighing the risk of relapse with patient wishes and desired quality of life? Dr. Walker will be discussing approaches to shared decision making in determining consolidation, maintenance, and transplantation for patients with AML.
Dr. Eunice S. Wang will discuss recommendations for the ongoing management of patients who are receiving these new treatments. While the advent of targeted therapies for AML has led to new hope for our patients, it has also introduced new challenges in management. Which patients benefit most from a specific therapy and what side effects should we watch for? When should you consider discontinuation of therapy? Are there patients who should move on to allogeneic stem cell transplantation rather than continue with the targeted agent? Dr. Wang will discuss the unique toxicities associated with mutation specific and non-specific agents and the risk/benefit ratio in decision making for individual patients.